Predictive Factors of Lapatinib and Capecitabine Activity in Patients with HER2-Positive, Trastuzumab-Resistant Metastatic Breast Cancer: Results from the Italian Retrospective Multicenter HERLAPAC Study

BACKGROUND: There are no validated predictive markers for lapatinib and capecitabine in patients with trastuzumab-resistant HER2 positive metastatic breast cancer. METHODS: Data of 148 consecutive patients treated with lapatinib and capecitabine from March 2007 to December 2013 were collected from 1...

Descripción completa

Detalles Bibliográficos
Autores principales: Gori, Stefania, Inno, Alessandro, Rossi, Valentina, Turazza, Monica, Fiorio, Elena, Fabi, Alessandra, Bisagni, Giancarlo, Foglietta, Jennifer, Santini, Daniele, Pavese, Ida, Pellegrino, Arianna, Zambelli, Alberto, Vici, Patrizia, Leonardi, Vita, Barni, Sandro, Saracchini, Silvana, Bogina, Giuseppe, Marchetti, Fabiana, Duranti, Simona, Lunardi, Gianluigi, Montemurro, Filippo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4880338/
https://www.ncbi.nlm.nih.gov/pubmed/27224517
http://dx.doi.org/10.1371/journal.pone.0156221

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4880338/
https://www.ncbi.nlm.nih.gov/pubmed/27224517
http://dx.doi.org/10.1371/journal.pone.0156221

Ejemplares similares